Skip to main content

Pancron D / R Side Effects

Generic name: pancrelipase

Medically reviewed by Last updated on Jan 25, 2021.

Note: This document contains side effect information about pancrelipase. Some of the dosage forms listed on this page may not apply to the brand name Pancron D / R.

For the Consumer

Applies to pancrelipase: oral capsule, oral capsule delayed release, oral tablet

Side effects requiring immediate medical attention

Along with its needed effects, pancrelipase (the active ingredient contained in Pancron D / R) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking pancrelipase:


With high doses

With very high doses

  • Blood in the urine
  • joint pain
  • swelling of the feet or lower legs

With powder dosage form or powder from opened capsules

- if breathed in
  • Stuffy nose
  • tightness in the chest
  • trouble breathing

With tablets

- if held in the mouth
  • Irritation of the mouth

Incidence not known

  • Cough
  • difficulty with swallowing
  • dizziness
  • fast heartbeat
  • itching
  • noisy breathing
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • redness of the skin
  • severe stomach pain
  • unusual tiredness or weakness

Side effects not requiring immediate medical attention

Some side effects of pancrelipase may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

Incidence not known

  • Difficulty having a bowel movement
  • difficulty with moving
  • muscle aching or cramping
  • muscle pains or stiffness
  • muscle spasm
  • swollen joints

For Healthcare Professionals

Applies to pancrelipase: oral capsule, oral capsule extended release, oral delayed release capsule, oral powder for reconstitution, oral tablet, oral tablet extended release


The most commonly reported side effects included gastrointestinal complaints, abdominal pain, and headaches.[Ref]


Bowel stricture formation occasionally occurred in children with cystic fibrosis who received high doses.

Moderate duodenitis and gastritis occurred in a patient with exocrine pancreatic insufficiency due to cystic fibrosis 16 days after completing treatment with 4000 lipase units/gram fat ingested per day for 5 to 6 days, followed by placebo for an additional 5 to 6 days.[Ref]

Very common (10% or more): Gastrointestinal complaints (up to 55%), abdominal pain (up to 18%), vomiting (up to 12%)

Common (1% to 10%): Abdominal discomfort, abdominal distention, abdominal pain upper, abdominal tenderness, abnormal feces, anal pruritus, ascites, constipation, diarrhea, dyspepsia, early satiety, flatulence, frequent bowel movements, nausea

Uncommon (0.1% to 1%): Bowel stricture formation

Frequency not reported: Duodenitis, fibrosing colonopathy, gastritis, steatorrhea, strictures of the ileocecum

Postmarketing reports: Distal intestinal obstruction syndrome (DIOS)[Ref]

Nervous system

Very common (10% or more): Headache (up to 15%)

Common (1% to 10%): Dizziness

Postmarketing reports: Dull headache[Ref]

A dull headache was reported by a patient receiving treatment with ursodeoxycholic acid concomitantly. The event resolved without sequelae after discontinuation of this drug.[Ref]


Common (1% to 10%): Blood cholesterol decreased, blood glucose increased, decreased appetite, diabetes mellitus, diabetes mellitus including subtypes, hyperglycemia, hypoglycemia, weight decreased

Frequency not reported: Hyperuricemia[Ref]


Common (1% to 10%): ALT increased, AST increased, biliary tract stones, blood alkaline phosphatase increased, cholangitis, GGT increased, hydrocholecystis

Postmarketing reports: Asymptomatic liver enzyme elevations[Ref]


Common (1% to 10%): Anemia, hematocrit, hemoglobin, red blood cell count, increased white blood cell count

Frequency not reported: Transient neutropenia with/without clinical sequelae[Ref]


Common (1% to 10%): Bronchitis, cough, nasopharyngitis, oropharyngeal pain, respiratory tract infection

Postmarketing reports: Asthma[Ref]


Common (1% to 10%): Asthenia, malaise, pain, pyrexia

Frequency not reported: Fatigue[Ref]


Common (1% to 10%): Pruritus, rash, skin reactions

Frequency not reported: Itching, urticaria/hives

Postmarketing reports: Blotchy/red facial rash[Ref]


Common (1% to 10%): Arthralgia, back pain, musculoskeletal pain

Postmarketing reports: Muscle spasm, myalgia[Ref]


Common (1% to 10%): Contusion, hypertension, peripheral edema[Ref]


Common (1% to 10%): Metastases to specific sites, recurrent pancreatic carcinoma

Postmarketing reports: Recurrence of preexisting carcinoma[Ref]


Common (1% to 10%): Insomnia, irritability[Ref]


Common (1% to 10%): Renal cyst[Ref]


Common (1% to 10%): Viral infection[Ref]


A patient with a known history of allergy to another pancrelipase (the active ingredient contained in Pancron D / R) product developed a mild allergic reaction, including red, blotchy facial rash and itching. The event resolved without sequelae after discontinuation of this drug.[Ref]

Frequency not reported: Anaphylactic reactions, hypersensitivity

Postmarketing reports: Anaphylaxis, mild allergic reactions, severe allergic reactions[Ref]


Frequency not reported: Hyperuricosuria[Ref]


Postmarketing reports: Blurred vision[Ref]


1. "Product Information. Ku-zyme (pancrelipase)." Schwarz Pharma, Mequon, WI.

2. "Product Information. Ultrase (pancrelipase)." Scandipharm Inc, Birmingham, AL.

3. "Product Information. Cotazym-S (pancrelipase)." Organon, West Orange, NJ.

4. "Product Information. Creon 10 (pancrelipase)." Solvay Pharmaceuticals Inc, Marietta, GA.

5. Cerner Multum, Inc. "Australian Product Information." O 0

6. "Product Information. Zymase (pancrelipase)." Organon, West Orange, NJ.

7. "Product Information. Pancrease (pancrelipase)." McNeil Pharmaceutical, Raritan, NJ.

8. "Product Information. Creon 20 (pancrelipase)." Solvay Pharmaceuticals Inc, Marietta, GA.

9. "Product Information. Ultrase MT (pancrelipase)." Scandipharm Inc, Birmingham, AL.

10. "Product Information. Cotazym (pancrelipase)." Organon, West Orange, NJ.

11. "Product Information. Viokase (pancrelipase)." Wyeth-Ayerst Laboratories, Philadelphia, PA.

12. "Product Information. Pancrease MT (pancrelipase)." McNeil Pharmaceutical, Raritan, NJ.

13. "Product Information. Creon 5 (pancrelipase)." Solvay Pharmaceuticals Inc, Marietta, GA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.